Kalmar Corporation's conveyance of own shares based on the long-term incentive plan

Udgivet den 12-03-2025  |  kl. 14:30  |  

KALMAR CORPORATION, STOCK EXCHANGE RELEASE, 12 MARCH 2025 AT 4:30 PM (EET) 

Kalmar Corporation's conveyance of own shares based on the long-term incentive plan

A total of 68,611 of Kalmar Corporation's treasury shares (class B) have been conveyed without consideration to 32 key persons based on the Performance Share Plan 2022-2024 (PSP 2022-2024), Restricted Share Plan 2022-2024 (RSP 2022-2024) and Restricted Share Plan 2023-2025 (RSP 2023-2025).

The directed share issue is based on an authorization given by the Annual General Meeting of Cargotec Corporation held on 30 May 2024 and the decision of the Kalmar Board of Directors on the transfer on 12 February 2025.

The shares were conveyed on 12 March 2025. After the conveyance Kalmar Corporation holds 181,389 of its own class B shares.

Kalmar announced the long-term incentive plans in a stock exchange release issued on 7 August 2024 and the payment based on the long-term incentive plans in a stock exchange release issued on 12 February 2025. More information on Kalmar's share based incentive plans is available on www.kalmarglobal.com.


For further information, please contact:
Carina Geber-Teir, SVP, IR, Marketing & Communications, tel. +358 40 502 4697

Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,200 people. In 2024, the company's sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com



\Hugin

Udgivet af: NPinvestordk

Mest læste lige nu

Novo får skåret kursmålet hos Jefferies efter skuffende Cagrisema-tal
Novo når primære endemål i vigtigt fase 3-studie for Cagrisema
Aktier/middag: Zealand brager i vejret på bekostning af Novo efter milliardaftale
Medie: Putin vil formentlig trække fredsforhandlinger i langdrag
Zealand Pharma på vej mod den største endagsstigning for et C25-selskab
 

Seneste nyheder

09:17 Aktier/åbning: Zealand tager gigantisk kurshop på milliardaftale
08:54 Obligationer/åbning: Flad renteudvikling før vigtig inflationsrapport
08:46 Zealands aktiekurs kan stige mere end 30 pct. spår Jefferies
08:43 Zealand Pharma har stor tiltro til kombination mellem kronjuvel og mulig "best in class"-molekyle
08:29 Råvarer: Svagere dollar sender oliepriserne i opadgående retning
08:22 Aktier/tendens: Zealand har udsigt til topplacering i ventet grønt marked
08:17 Zealand Pharma har fundet en partner til Petrelintid: Topchef ser enormt potentiale i overskudsdeling
08:00 Tysk våbenproducent skruer lidt ned for salgsvæksten i år efter rekord i 2024
07:37 Zealand har fået gigantaftale med wauw-effekt i hus mener Nordnet
07:32 Obligationer/tendens: Nye rentestigninger i sigte med fokus på amerikansk inflation
07:22 Zealand Pharma finder schweizisk partner til sin kronjuvel
07:06 Novo får skåret kursmålet hos Jefferies efter skuffende Cagrisema-tal
06:58 EU vil indføre nye afgifter som svar på amerikansk told
06:49 DSV får købsanbefaling hos Jefferies: Ser positivt på strategi og Schenker-opkøb
06:38 Genmab får skåret kursmålet hos Morgan Stanley efter Hexabody-afgørelse
06:37 Asien: Bekymrede investorer forsøger at finde fodfæste
06:35 EU vil lægge told på varer fra USA for 26 mia. euro.
06:34 Ukraine støtter forslag om våbenhvile - USA genoptager militær støtte
06:34 Trump dropper toldfordobling - Ontario suspenderer eksporttold
06:34 Nordea får kursmålet sænket med 5 pct. hos Citi